NorthStar Medical Radioisotopes Participates in "Coolest Thing Made in Wisconsin" Competition with RadioGenix® System
‒ Voting Begins September 9, 2019 at www.madeinwis.com ‒
Beloit, Wis., September 9, 2019 – NorthStar Medical Radioisotopes, LLC, a global innovator in the production and distribution of radioisotopes used for medical imaging, today announced its participation in the 4th Annual Coolest Thing Made in Wisconsin contest. The event highlights Wisconsin’s vibrant manufacturing industry, its innovative products and available career opportunities available in Wisconsin’s largest economic industry. NorthStar nominated its RadioGenix® System (technetium Tc 99m generator) as a candidate for the Coolest Thing Made in Wisconsin.
Manufactured in Wisconsin, the RadioGenix System is an innovative, high technology platform that is approved and commercially available to produce technetium-99m (Tc-99m), a widely used medical radioisotope important for 40,000 patients daily in the U.S. who require diagnostic imaging tests. Tc-99m is obtained from another radioisotope, molybdenum-99 (Mo-99). The proprietary RadioGenix System uses U.S.-produced, non-uranium based material and an environmentally friendly production process to produce Tc-99m rather than overseas, uranium-based production. Before RadioGenix technology became available, the supply of Mo-99 in the United States has experienced frequent and sometimes severe interruptions which negatively impact patient healthcare. The RadioGenix System is the first and only automated isotope separation system of its kind for use with non-uranium based Mo-99, and is designed to help alleviate shortage situations and expand domestic radioisotope supply for patients needing important diagnostic imaging tests.
The Coolest Thing Made in Wisconsin is presented by Wisconsin Manufacturers & Commerce (WMC) and Johnson Financial Group. A popular vote from September 9 to September 16 will determine the Top 16 products that will be placed in a bracket-style tournament called Manufacturing Madness. Products will compete against one another in head-to-head match-ups, and the products that receive the highest votes in each match-up will advance to the next round, with the winner being announced on October 8, 2019. Votes can be cast at: www.madeinwis.com.
Indication and Important Risk Information about the RadioGenix® System and Sodium Pertechnetate Tc 99m Injection USP
The RadioGenix® System is a technetium Tc-99m generator used to produce Sodium Pertechnetate Tc 99m Injection, USP. Sodium Pertechnetate Tc 99m Injection is a radioactive diagnostic agent and can be used in the preparation of FDA-approved diagnostic radiopharmaceuticals.
Sodium Pertechnetate Tc 99m Injection is also indicated in
• Adults for Salivary Gland Imaging and Nasolacrimal Drainage System Imaging (dacryoscintigraphy).
• Adults and pediatric patients for Thyroid Imaging and Vesicoureteral Imaging (direct isotopic cystography) for detection of vesicoureteral reflux.
IMPORTANT RISK INFORMATION
• Allergic reactions (skin rash, hives, or itching) including anaphylaxis have been reported following the administration of Sodium Pertechnetate Tc 99m Injection. Monitor all patients for hypersensitivity reactions.
• Radiation risks associated with the use of Sodium Pertechnetate Tc 99m Injection are greater in children than in adults and, in general, the younger the child, the greater the risk owing to greater absorbed radiation doses and longer life expectancy. These greater risks should be taken firmly into account in all benefit-risk assessments involving children. Long-term cumulative radiation exposure may be associated with an increased risk of cancer.
• Temporarily discontinue breastfeeding. A lactating woman should pump and discard breastmilk for 12 to 24 hours after Sodium Pertechnetate Tc 99m Injection administration.
• Sodium Pertechnetate Tc 99m Injection should be given to pregnant women only if the expected benefits to be gained clearly outweigh the potential hazards.
• Only use potassium molybdate Mo-99, processing reagents, saline and other supplies, including kits, provided by NorthStar Medical Radioisotopes. Do not administer Sodium Pertechnetate Tc 99m Injection after the 0.15 microCi of Mo-99/mCi of Tc-99m limit has been reached or when the 12 hour expiration time from elution is reached, whichever occurs earlier.
To report SUSPECTED ADVERSE REACTIONS, contact NorthStar Medical Radioisotopes, LLC at 1-844-438-6659; or FDA at 1-800-332-1088 or http://www.fda.gov/medwatch.
For Full RadioGenix® System Prescribing Information, click here or visit
About NorthStar Medical Radioisotopes, LLC (NorthStar)
Wisconsin-based NorthStar Medical Radioisotopes is a nuclear medicine technology company committed to providing the United States with reliable and environmentally friendly radioisotope supply solutions to meet the needs of patients and to advance clinical research. Its first product, the RadioGenix® System, is an FDA-approved and commercially available innovative platform technology for processing non-uranium based molybdenum-99 (Mo-99), the parent isotope of technetium-99m (Tc-99m), which is currently the most widely used diagnostic radioisotope for medical purposes. NorthStar’s proprietary and patented technologies include non-uranium based molybdenum-99 domestic production methods, patented separation chemistry systems, patented sterilization systems and a technology platform that potentially allows expanded product offerings to provide solutions in both the diagnostic and therapeutic markets. NorthStar is headquartered in Beloit, Wis. and employees approximately 170 people. NorthStar Medical Radioisotopes, LLC is a wholly-owned subsidiary of NorthStar Medical Technologies, LLC. For more information, visit: www.northstarnm.com.
For NorthStar Medical Radioisotopes, LLC
Vice President Sales and Marketing